# Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

> **NCT04848454** · PHASE2 · UNKNOWN · sponsor: **Peking University First Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HER2-negative Breast Cancer
- Neoadjuvant Therapy
- Pathological Complete Response
- Immunotherapy
- Vinorelbine
- Cisplatin

## Interventions

- **DRUG:** Camrelizumab with vinorelbine and cisplatin

## Key facts

- **NCT ID:** NCT04848454
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-20
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04848454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04848454, "Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04848454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*